2.
Relationships between c-MET amplification and clinicopathologic features (N=326)
| Variables | MET qPCR <5 in gCN | MET qPCR ≥5 in gCN | P |
| ECOG PS, Eastern Cooperative Oncology Group performance status; WD, well differentiated; MD, moderate differentiated; PD, poorly differentiated; SRC, signet ring cell carcinoma; LN, lymph node; UNL, upper normal limit; WBC, white blood cells; ALP, alkaline phosphatase; qPCR, quantitative polymerase chain reaction; gCN, gene copy number. *, hemoglobin ≤12 g/dL for women and ≤13 g/dL for men; **, initial complete blood count, alkaline phosphatase and bilirubin levels, and scores from the Asan Medical Center prognostic model were not available in 9 patients (2.8%); ***, albumin level was not available in 11 patients (3.4%). | |||
| Sex | |||
| Male | 214 (70.2) | 11 (52.4) | 0.088 |
| Female | 91 (29.8) | 10 (47.6) | |
| Age (year) | |||
| <65 | 226 (74.1) | 17 (81.0) | 0.486 |
| ≥65 | 79 (25.9) | 4 (19.0) | |
| ECOG PS | |||
| 0−1 | 273 (89.5) | 14 (66.7) | 0.007 |
| 2−3 | 32 (10.5) | 7 (33.3) | |
| Bormann type | |||
| I/II/III | 247 (84.0) | 18 (85.7) | 1.000 |
| IV | 47 (16.0) | 3 (14.3) | |
| Histology | |||
| WD/MD | 111 (37.1) | 6 (28.6) | 0.432 |
| PD/SRC/mucinous | 188 (62.9) | 15 (71.4) | |
| HER2 expression | |||
| Negative | 98 (32.1) | 5 (23.8) | 0.594 |
| Positive | 17 (5.6) | 2 (9.5) | |
| Not available | 190 (62.3) | 14 (66.7) | |
| Disease status | |||
| Initially metastatic | 198 (64.9) | 17 (81.0) | 0.263 |
| Recurred | 94 (30.8) | 4 (19.0) | |
| Locally advanced | 13 (4.3) | 0 (0) | |
| Peritoneal metastasis | |||
| No | 164 (53.8) | 5 (23.8) | 0.008 |
| Yes | 141 (46.2) | 16 (76.2) | |
| Liver metastasis | |||
| No | 218 (71.5) | 14 (66.7) | 0.804 |
| Yes | 87 (28.5) | 7 (33.3) | |
| Lung metastasis | |||
| No | 287 (94.1) | 19 (90.5) | 0.804 |
| Yes | 18 (5.9) | 2 (9.5) | |
| Distant LN metastasis | |||
| No | 157 (51.5) | 8 (38.1) | 0.236 |
| Yes | 148 (48.5) | 13 (61.9) | |
| Bone metastasis | |||
| No | 282 (92.5) | 17 (81.0) | 0.084 |
| Yes | 23 (7.5) | 4 (19.0) | |
| Hemoglobin*,** | |||
| >UNL | 91 (30.7) | 4 (19.0) | 0.258 |
| ≤UNL | 205 (69.3) | 17 (81.0) | |
| WBC (mm3)** | |||
| <10,000 | 253 (85.5) | 17 (81.0) | 0.751 |
| ≥10,000 | 43 (14.5) | 4 (19.0) | |
| Platelet (×103/mm3)** | |||
| >150 | 260 (87.8) | 19 (90.5) | 0.761 |
| ≤150 | 36 (12.2) | 2 (9.5) | |
| Albumin (g/dL)*** | |||
| >3.3 | 201 (68.4) | 10 (47.6) | 0.051 |
| ≤3.3 | 93 (31.6) | 11 (52.4) | |
| ALP (IU/L)** | |||
| ≤120 | 234 (79.1) | 13 (61.9) | 0.098 |
| >120 | 62 (20.9) | 8 (38.1) | |
| Total bilirubin (mg/dL)** | |||
| ≤1.2 | 274 (92.6) | 15 (71.4) | 0.006 |
| >1.2 | 22 (7.4) | 6 (28.6) | |
| Asan medical center prognostic model** | |||
| Good (0−1) | 147 (49.7) | 7 (33.3) | 0.001 |
| Moderate (2−3) | 107 (36.1) | 4 (19.0) | |
| Poor (≥4) | 42 (14.2) | 10 (47.6) | |